A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials

Motivation: COVID-19 has fast-paced drug re-positioning for its treatment. This work builds computational models for the same. The aim is to assist clinicians with a tool for selecting prospective antiviral treatments. Since the virus is known to mutate fast, the tool is likely to help clinicians in selecting the right set of antivirals for the mutated isolate. Results: The main contribution of this work is a manually curated database publicly shared, comprising of existing associations between viruses and their corresponding antivirals. The database gathers similarity information using the chemical structure of drugs and the genomic structure of viruses. Along with this database, we make available a set of state-of-the-art computational drug re-positioning tools based on matrix completion. The tools are first analysed on a standard set of experimental protocols for drug target interactions. The best performing ones are applied for the task of re-positioning antivirals for COVID-19. These tools select six drugs out of which four are currently under various stages of trial, namely Remdesivir (as a cure), Ribavarin (in combination with others for cure), Umifenovir (as a prophylactic and cure) and Sofosbuvir (as a cure). Another unanimous prediction is Tenofovir alafenamide, which is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both are under trail, the former as a cure and the latter as a prophylactic. These results establish that the computational methods are in sync with the state-of-practice. We also demonstrate how the selected drugs change as the SARS-Cov-2 mutates over time, suggesting the importance of such a tool in drug prediction. Availability: The database along with a set of 6 state-of-the-art matrix completion computational methods and their associated prediction results are made available publicly at https://github.com/aanchalMongia/DVA.

[1]  Angshul Majumdar,et al.  Drug-target interaction prediction using Multi Graph Regularized Nuclear Norm Minimization , 2020, PloS one.

[2]  Trevor J. Hastie,et al.  Matrix completion and low-rank SVD via fast alternating least squares , 2014, J. Mach. Learn. Res..

[3]  Wei Zhang,et al.  Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. , 2020, Bioscience trends.

[4]  Guangdi Li,et al.  Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.

[5]  David Selwood,et al.  Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala , 2005, Molecular Cancer Therapeutics.

[6]  Hugues Talbot,et al.  A Majorize-Minimize Subspace Approach for ℓ2-ℓ0 Image Regularization , 2011, SIAM J. Imaging Sci..

[7]  Y. Ohashi,et al.  Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection , 2010, Antimicrobial Agents and Chemotherapy.

[8]  Prabhu Babu,et al.  Majorization-Minimization Algorithms in Signal Processing, Communications, and Machine Learning , 2017, IEEE Transactions on Signal Processing.

[9]  Mayank Vatsa,et al.  Deep Dictionary Learning , 2016, IEEE Access.

[10]  Chee Keong Kwoh,et al.  Drug-Target Interaction Prediction with Graph Regularized Matrix Factorization , 2017, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[11]  Jie Ren,et al.  Alignment-free \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{upgreek} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} }{}$d_2^*$\end{document} oligonucleotide frequency dissi , 2016, Nucleic acids research.

[12]  Angshul Majumdar,et al.  McImpute: Matrix Completion Based Imputation for Single Cell RNA-seq Data , 2018, bioRxiv.

[13]  Angshul Majumdar,et al.  Computational prediction of Drug-Disease association based on Graph-regularized one bit Matrix completion , 2020, bioRxiv.

[14]  A. Chopra,et al.  Effectiveness of Chloroquine and Inflammatory Cytokine Response in Patients With Early Persistent Musculoskeletal Pain and Arthritis Following Chikungunya Virus Infection , 2014, Arthritis & rheumatology.

[15]  Charlotte Harrison,et al.  Coronavirus puts drug repurposing on the fast track , 2020, Nature Biotechnology.

[16]  S. Chattopadhyay,et al.  Heat Shock Protein 90 Positively Regulates Chikungunya Virus Replication by Stabilizing Viral Non-Structural Protein nsP2 during Infection , 2014, PloS one.

[17]  Emmanuel J. Candès,et al.  The Power of Convex Relaxation: Near-Optimal Matrix Completion , 2009, IEEE Transactions on Information Theory.

[18]  J. Huggins.  Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.

[19]  R. Razonable.  Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus , 2011, Mayo Clinic Proceedings.

[20]  V. S. Santos,et al.  No current evidence supporting risk of using Ibuprofen in patients with COVID‐19 , 2020, International journal of clinical practice.

[21]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[22]  Susumu Goto,et al.  SIMCOMP/SUBCOMP: chemical structure search servers for network analyses , 2010, Nucleic Acids Res..

[23]  Dirk Van den Poel,et al.  Handling class imbalance in customer churn prediction , 2009, Expert Syst. Appl..

[24]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[25]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[26]  X. He,et al.  Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol , 2020, Chinese medical journal.

[27]  S. Chatterjee.  An Overview of Mutations Occurring within the Coronavirus-2 Genome: Mutations Data Reporting on SARS-CoV-2 , 2020 .

[28]  M. Ciccozzi,et al.  Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant , 2020, Journal of Translational Medicine.

[29]  T. Liang,et al.  Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial , 2020, European Journal of Pharmaceutical Sciences.

[30]  Chee-Keong Kwoh,et al.  Computational prediction of drug-target interactions using chemogenomic approaches: an empirical survey , 2019, Briefings Bioinform..

[31]  Nelly Pustelnik,et al.  Parallel Proximal Algorithm for Image Restoration Using Hybrid Regularization , 2009, IEEE Transactions on Image Processing.

[32]  Aanchal Mongia,et al.  Deep Matrix Completion on Graphs: Application in Drug Target Interaction Prediction , 2020, ICASSP 2020 - 2020 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP).

[33]  Emmanuel J. Candès,et al.  Exact Matrix Completion via Convex Optimization , 2008, Found. Comput. Math..

[34]  I. M. Otivation.  Playing with Duality: An Overview of Recent Primal-Dual Approaches for Solving Large-Scale Optimization Problems , 2018 .

[35]  Stephen P. Boyd,et al.  Distributed Optimization and Statistical Learning via the Alternating Direction Method of Multipliers , 2011, Found. Trends Mach. Learn..

[36]  A. Strongin,et al.  Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis , 2017, Scientific Reports.

[37]  Yun Zhang,et al.  ViPR: an open bioinformatics database and analysis resource for virology research , 2011, Nucleic Acids Res..

[38]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[39]  M. Hussain,et al.  Drug resistance in influenza A virus: the epidemiology and management , 2017, Infection and drug resistance.

[40]  G. Drusano,et al.  Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a. , 2016, The Journal of infectious diseases.

[41]  Angshul Majumdar,et al.  deepMc: deep Matrix Completion for imputation of single cell RNA-seq data , 2018, bioRxiv.

[42]  Raymond T Chung,et al.  Anti-hepatitis C virus drugs in development. , 2012, Gastroenterology.

[43]  L. Guddat,et al.  Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug , 2020 .

[44]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[45]  N. Mygind,et al.  Potential benefits of ibuprofen in the treatment of viral respiratory infections , 2004, InflammoPharmacology.

[46]  S. Frantz.  Drug discovery: Playing dirty , 2005, Nature.

[47]  K. Jenpanich,et al.  [Drug administration]. , 1976, Thai journal of nursing.

[48]  Y. Duan,et al.  Advance of promising targets and agents against COVID-19 in China , 2020, Drug Discovery Today.

[49]  M. Ferrer,et al.  Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection , 2015, Science Translational Medicine.

[50]  R. Sanjuán,et al.  Viral Mutation Rates , 2010, Journal of Virology.

[51]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..